FDA Clears iRhythm’s Afib-Detecting Wearable Running Software Co-Developed By Verily
Executive Summary
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
You may also be interested in...
News We’re Watching: May Health PCOS Treatment Shows Promise, Roche Adds Alzheimer’s Assays, Luciole Buys Spiegelberg
This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.
Cardio Conversations: iRhythm Prepares To Deliver ‘Standard-Of-Care’ Cardiac Monitoring
Quentin Blackford, CEO of iRhythm, talked to Medtech Insight about his company’s plans to bring its Zio long-term cardiac monitoring platform to more patients by building its evidence base and marketing in more countries outside the US.
Digital Disruption, E-Commerce And Developing Markets Key For OTC Spin-Out Success
Building digital capabilities to ward off tech disruption from outside industry, making the most of the e-pharmacy boom, and living up to ESG commitments by investing in developing markets are all ways OTC spin-out companies can make the most of their new found independence, according to IQVIA Consumer Health.